Recordati is an Italian specialty pharmaceutical group focused on treatments for rare diseases as well as selected primary-care and specialty products. It combines in-house development and licensing with a European commercial network and growing international reach. Its portfolio spans cardiovascular, urology, allergy and orphan therapies sold mainly to hospitals, specialists and retail pharmacies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 643.9 | — | 91.1 | — |
| Q3 2025 | 632.3 | — | 110.2 | — |
| Q4 2025 | 662.2 | — | 117.3 | — |
| Q1 2026 | 713.4 | — | 153.1 | — |
| Q2 2026 | 697.4 | 8.3% | 116.6 | 28% |
All markets — KeepWinning global stock screener
Other companies on Borsa Italiana (Milan): Edison S.p.A. (EDNR), Italgas S.p.A. (IG), Banca Generali S.p.A. (BGN), Buzzi S.p.A. (BZU), A2A S.p.A. (A2A), Pirelli & C. S.p.A. (PIRC)